This page has only limited features, please log in for full access.

Unclaimed
Chieh-Lin Teng
School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 30 August 2021 in Journal of Clinical Medicine
Reads 0
Downloads 0

Thromboembolism is a critical event in patients with coronavirus disease (COVID)-19 infection and highly associated with neutrophil extracellular traps. D-dimer has been found to be an essential thromboembolism-associated biomarker; however, the association between absolute neutrophil count (ANC) and level of D-dimer in patients with COVID-19 infection remains unclear. In this study, we enrolled consecutive patients with COVID-19 admitted to Taichung Veterans General Hospital (TCVGH), a referral center in central Taiwan with 20 airborne infection isolation rooms. Spearman correlation was used to determine the association between ANC and level of D-dimer in distinct time periods. A total of 28 consecutive patients with COVID-19 infection were enrolled, and 32.1% (9/28) of them required mechanical ventilation. Patients requiring mechanical ventilation had a higher ANC (8225 vs. 3427/µL, p< 0.01) and levels of D-dimer (6.0 vs. 0.6 mg/L, p< 0.01) compared with those without mechanical ventilation. Notably, we identified five patients with image-proven thromboembolic events during the hospital course, with the number of patients with pulmonary embolism, venous thrombosis and acute ischemic stroke were 2, 1, and 2, respectively. We found that ANC within 4 days correlated with the level of D-dimer to a moderate level (r = 0.71, p< 0.05), and the association between ANC and D-dimer no longer exist after day 5. In conclusion, we found highly prevalent thromboembolic events among patients with severe COVID-19 infection in central Taiwan and identified the association between early ANC and D-dimer. More studies are warranted to elucidate the underlying mechanism.

ACS Style

Wen-Cheng Chao; Chieh-Liang Wu; Jin-An Huang; Jyh-Wen Chai; Chieh-Lin Teng; Wen-Lieng Lee; Yun-Ching Fu; Shih-Ann Chen. Association between Early Absolute Neutrophil Count and Level of D-Dimer among Patients with COVID-19 Infection in Central Taiwan. Journal of Clinical Medicine 2021, 10, 3891 .

AMA Style

Wen-Cheng Chao, Chieh-Liang Wu, Jin-An Huang, Jyh-Wen Chai, Chieh-Lin Teng, Wen-Lieng Lee, Yun-Ching Fu, Shih-Ann Chen. Association between Early Absolute Neutrophil Count and Level of D-Dimer among Patients with COVID-19 Infection in Central Taiwan. Journal of Clinical Medicine. 2021; 10 (17):3891.

Chicago/Turabian Style

Wen-Cheng Chao; Chieh-Liang Wu; Jin-An Huang; Jyh-Wen Chai; Chieh-Lin Teng; Wen-Lieng Lee; Yun-Ching Fu; Shih-Ann Chen. 2021. "Association between Early Absolute Neutrophil Count and Level of D-Dimer among Patients with COVID-19 Infection in Central Taiwan." Journal of Clinical Medicine 10, no. 17: 3891.

Journal article
Published: 09 June 2021 in Biomolecules
Reads 0
Downloads 0

Medullary thyroid cancer (MTC) is a neuroendocrine tumor that arises from the parafollicular C-cells, which produces the hormone calcitonin. RET is a transmembrane receptor protein-tyrosine kinase, which is highly expressed in MTC. Our previous studies reported that cyclin-dependent kinase 5 (CDK5) plays a crucial role in cancer progression, including MTC. However, the role of CDK5 in GDNF-induced RET signaling in medullary thyroid cancer proliferation remains unknown. Here, we investigated RET activation and its biochemically interaction with CDK5 in GDNF-induced medullary thyroid cancer proliferation. Our results demonstrated that GDNF stimulated RET phosphorylation and thus subsequently resulted in CDK5 activation by its phosphorylation. Activated CDK5 further caused STAT3 activation by its specific phosphorylation at Ser727. Moreover, we also found that GDNF treatment enhanced ERK1/2 and EGR1 activity, which is involved in p35 activation. Interestingly, we identified for the first time that CDK5 physically interacted with RET protein in MTC. Overall, our results provide a new mechanism for medullary thyroid cancer cell proliferation, suggesting that targeting CDK5 may be a promising therapeutic candidate for human medullary thyroid cancer in the near future.

ACS Style

Chia-Herng Yue; Muhammet Oner; Chih-Yuan Chiu; Mei-Chih Chen; Chieh-Lin Teng; Hsin-Yi Wang; Jer-Tsong Hsieh; Chih-Ho Lai; Ho Lin. RET Regulates Human Medullary Thyroid Cancer Cell Proliferation through CDK5 and STAT3 Activation. Biomolecules 2021, 11, 860 .

AMA Style

Chia-Herng Yue, Muhammet Oner, Chih-Yuan Chiu, Mei-Chih Chen, Chieh-Lin Teng, Hsin-Yi Wang, Jer-Tsong Hsieh, Chih-Ho Lai, Ho Lin. RET Regulates Human Medullary Thyroid Cancer Cell Proliferation through CDK5 and STAT3 Activation. Biomolecules. 2021; 11 (6):860.

Chicago/Turabian Style

Chia-Herng Yue; Muhammet Oner; Chih-Yuan Chiu; Mei-Chih Chen; Chieh-Lin Teng; Hsin-Yi Wang; Jer-Tsong Hsieh; Chih-Ho Lai; Ho Lin. 2021. "RET Regulates Human Medullary Thyroid Cancer Cell Proliferation through CDK5 and STAT3 Activation." Biomolecules 11, no. 6: 860.

Oncology
Published: 28 May 2021 in Frontiers in Oncology
Reads 0
Downloads 0

Background The therapeutic options of relapsed or refractory multiple myeloma (RRMM) remain a challenge. The MM-003 trial demonstrated that RRMM patients treated with pomalidomide and dexamethasone (Pom/Dex) have better progression-free survival (PFS) than those treated with high-dose dexamethasone alone. However, the real-world effectiveness of Pom/Dex in these patients in Taiwan remains unclear. Methods This multicenter, registry-based study retrospectively reviewed the medical records of 49 consecutive patients undergoing Pom/Dex treatment for RRMM. We investigated the overall response rate (ORR) and PFS in these patients. The patients were stratified into two groups: those who received two (n=33) and those who received more than two (n=16) prior lines of treatment according to the numbers of regimens before Pom/Dex therapy. The differences in ORR and PFS between these two groups were further analyzed. We also analyzed factors attributed to disease progression. Results The ORR was 47.7%, and the median PFS was 4.0 months (range, 0.1−21.1). Patients who received two prior lines of treatment had a higher ORR than those who received more than two prior lines of treatment (55.2% vs. 33.3%; p=0.045). The median PFS of these groups was 4.8 and 3.9 months, respectively (p=0.805). Primary lenalidomide refractoriness reduced the risk of myeloma progression following Pom/Dex treatment (hazard ratio, 0.14; p=0.001). Conclusions The median PFS following Pom/Dex treatment in Taiwanese RRMM patients in a real-world setting was similar to that reported by the MM-003 trial. Primary lenalidomide refractoriness should not be an obstacle for Pom/Dex treatment in RRMM.

ACS Style

Yu-Chin Hung; Jyh-Pyng Gau; Shang-Yi Huang; Bor-Sheng Ko; Chieh-Lin Jerry Teng. Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan. Frontiers in Oncology 2021, 11, 1 .

AMA Style

Yu-Chin Hung, Jyh-Pyng Gau, Shang-Yi Huang, Bor-Sheng Ko, Chieh-Lin Jerry Teng. Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan. Frontiers in Oncology. 2021; 11 ():1.

Chicago/Turabian Style

Yu-Chin Hung; Jyh-Pyng Gau; Shang-Yi Huang; Bor-Sheng Ko; Chieh-Lin Jerry Teng. 2021. "Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan." Frontiers in Oncology 11, no. : 1.

Letter to the editor
Published: 13 January 2021 in Annals of Hematology
Reads 0
Downloads 0
ACS Style

Po-Wei Liao; Ren Ching Wang; Tsung-Chih Chen; Chieh-Lin Jerry Teng. Venetoclax-induced panniculitis in an acute myeloid leukemia patient. Annals of Hematology 2021, 100, 1333 -1334.

AMA Style

Po-Wei Liao, Ren Ching Wang, Tsung-Chih Chen, Chieh-Lin Jerry Teng. Venetoclax-induced panniculitis in an acute myeloid leukemia patient. Annals of Hematology. 2021; 100 (5):1333-1334.

Chicago/Turabian Style

Po-Wei Liao; Ren Ching Wang; Tsung-Chih Chen; Chieh-Lin Jerry Teng. 2021. "Venetoclax-induced panniculitis in an acute myeloid leukemia patient." Annals of Hematology 100, no. 5: 1333-1334.

Research article
Published: 01 January 2021 in Therapeutic Advances in Hematology
Reads 0
Downloads 0

Background: Letermovir prophylaxis is currently the standard of care for the prevention of cytomegalovirus (CMV) infections in allogeneic hematopoietic stem-cell transplantation (allo-HSCT). However, drug–drug interactions between letermovir and azoles or calcineurin inhibitors and the high financial burden of letermovir remain problematic, especially in resource-limited countries. It has not been clarified whether a lower dose of valganciclovir would constitute an effective strategy for CMV prevention in patients with acute leukemia undergoing allo-HSCT. Methods: We retrospectively assessed 84 consecutive adult patients with acute leukemia who underwent allo-HSCT. These 84 patients were stratified into a valganciclovir prophylaxis group ( n = 20) and a non-valganciclovir prophylaxis group ( n = 64). Results: Patients in the valganciclovir prophylaxis group had a lower possibility of CMV DNAemia at week 14 after allo-HSCT than those in the non-valganciclovir prophylaxis group (15.0% versus 50.0%; p = 0.012). The cumulative incidence of CMV DNAemia at week 14 was also lower in patients with valganciclovir CMV prophylaxis than in those without (15.0% versus 50.4%; p = 0.006). Multivariate analysis validated these data, showing that a low dose of valganciclovir significantly reduced the risk of CMV DNAemia at week 14 by 88% (hazard ratio: 0.12; 95% confidence interval: 0.04–0.42; p = 0.001). However, these two groups had similar overall survival rates at week 48 (75.0% versus 76.6%; p = 0.805). Four of 20 (20%) patients discontinued valganciclovir prophylaxis because of adverse events. Conclusion: Low-dose valganciclovir prophylaxis could be an alternative to letermovir to prevent CMV infection in allo-HSCT, especially in resource-limited countries.

ACS Style

Po-Hsien Li; Cheng-Hsien Lin; Yu-Hui Lin; Tsung-Chih Chen; Chiann-Yi Hsu; Chieh-Lin Jerry Teng. Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation. Therapeutic Advances in Hematology 2021, 12, 1 .

AMA Style

Po-Hsien Li, Cheng-Hsien Lin, Yu-Hui Lin, Tsung-Chih Chen, Chiann-Yi Hsu, Chieh-Lin Jerry Teng. Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation. Therapeutic Advances in Hematology. 2021; 12 ():1.

Chicago/Turabian Style

Po-Hsien Li; Cheng-Hsien Lin; Yu-Hui Lin; Tsung-Chih Chen; Chiann-Yi Hsu; Chieh-Lin Jerry Teng. 2021. "Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation." Therapeutic Advances in Hematology 12, no. : 1.

Research article
Published: 01 January 2021 in Therapeutic Advances in Hematology
Reads 0
Downloads 0

Background and aims: The application of QuantiFERON-TB Gold in-Tube (QFT-GIT) in patients with haematological malignancies (HMs) has not been well studied. Therefore, we aimed to investigate the features of patients with HMs whose QFT-GIT results were indeterminate. Methods: This study enrolled patients with HMs for the analysis of QFT-GIT tests and additional 2-year follow-up. The characteristics and predictors of QFT-GIT indeterminate results were identified. Mycobacterium tuberculosis (TB) incidence rate (IR) and incidence rate ratio (IRR) were also investigated. Results: Of 89 participants, 27 (30.3%) had QFT-GIT indeterminate results. The QFT-GIT indeterminate patients were characterized with the diagnosis of leukaemia (63.0% versus 32.3%, p = 0.044), abnormal white blood count (WBC) (88.9% versus 14.5%, p = 0.001), abnormal lymphocyte percentage (81.5% versus 14.5%, p = 0.001) and lower lymphocyte count (×109/l) (0.5 versus 2.2, p = 0.000) when compared with those with determinate results. Meanwhile, abnormal WBC [odds ratios (OR): 15.18, p = 0.003] and lymphocyte percentage (OR: 6.90, p = 0.033) were predictors of indeterminate results. One patient with the QFT-GIT indeterminate status and high interferon-γ level of negative control result developed active TB with a TB IR of 18.5 per 1000 person-years and an IRR of 0.1 (95% confidence interval, 0.01–0.71) when compared with positive QFT-GIT patients without prophylaxis treatment. Conclusion: Abnormal ranges of WBC and lymphocyte differential count percentage were independent predictors useful to determine the optimal timing of implementing QFT-GIT test in patients with HMs.

ACS Style

Chen-Cheng Huang; Chieh-Lin Jerry Teng; Ming-Feng Wu; Ching-Hsiao Lee; Hui-Chen Chen; Wei-Chang Huang. Features of indeterminate results of QuantiFERON-TB Gold In-Tube test in patients with haematological malignancies. Therapeutic Advances in Hematology 2021, 12, 1 .

AMA Style

Chen-Cheng Huang, Chieh-Lin Jerry Teng, Ming-Feng Wu, Ching-Hsiao Lee, Hui-Chen Chen, Wei-Chang Huang. Features of indeterminate results of QuantiFERON-TB Gold In-Tube test in patients with haematological malignancies. Therapeutic Advances in Hematology. 2021; 12 ():1.

Chicago/Turabian Style

Chen-Cheng Huang; Chieh-Lin Jerry Teng; Ming-Feng Wu; Ching-Hsiao Lee; Hui-Chen Chen; Wei-Chang Huang. 2021. "Features of indeterminate results of QuantiFERON-TB Gold In-Tube test in patients with haematological malignancies." Therapeutic Advances in Hematology 12, no. : 1.

Research article
Published: 01 January 2020 in Therapeutic Advances in Hematology
Reads 0
Downloads 0

Background: Posaconazole prophylaxis during remission induction chemotherapy not only decreases the incidence of invasive aspergillosis (IA) but also improves the overall survival rate among patients with acute myeloid leukemia (AML). However, it remains debatable whether this result applies to patients in a real-world setting. Methods: We retrospectively assessed 208 adult patients with newly diagnosed AML who underwent remission induction therapy. These 208 patients were stratified into the posaconazole prophylaxis group ( n = 58) and no antifungal prophylaxis group ( n = 150). Results: Multivariate analyses showed that induction failure significantly increased the risk of proven or probable IA during the first induction chemotherapy [hazard ratio (HR), 10.47; 95% confidence interval (CI), 1.73–63.45; p = 0.011] and the entire course of AML treatment (HR, 4.48; 95% CI, 1.71–11.75; p = 0.002). However, posaconazole prophylaxis did not reduce the risk of IA during the first induction chemotherapy (HR, 1.47; 95% CI, 0.14–15.04; p = 0.746) and during the entire course of AML treatment (HR, 1.09; 95% CI, 0.29–4.09; p = 0.896). Furthermore, there was no significant difference in overall survival between these two groups of patients (514 versus 689 days; p = 0.454). Conclusion: Successful induction remains fundamental to reducing the risk of IA among AML patients undergoing remission induction chemotherapy.

ACS Style

Tsung-Chih Chen; Ren Ching Wang; Yu-Hui Lin; Kuang-Hsi Chang; Li-Ya Hung; Chieh-Lin Jerry Teng. Posaconazole for the prophylaxis of invasive aspergillosis in acute myeloid leukemia: Is it still useful outside the clinical trial setting? Therapeutic Advances in Hematology 2020, 11, 1 .

AMA Style

Tsung-Chih Chen, Ren Ching Wang, Yu-Hui Lin, Kuang-Hsi Chang, Li-Ya Hung, Chieh-Lin Jerry Teng. Posaconazole for the prophylaxis of invasive aspergillosis in acute myeloid leukemia: Is it still useful outside the clinical trial setting? Therapeutic Advances in Hematology. 2020; 11 ():1.

Chicago/Turabian Style

Tsung-Chih Chen; Ren Ching Wang; Yu-Hui Lin; Kuang-Hsi Chang; Li-Ya Hung; Chieh-Lin Jerry Teng. 2020. "Posaconazole for the prophylaxis of invasive aspergillosis in acute myeloid leukemia: Is it still useful outside the clinical trial setting?" Therapeutic Advances in Hematology 11, no. : 1.

Journal article
Published: 20 August 2019 in European Journal of Haematology
Reads 0
Downloads 0

This study explored resistance functions and their interactions in de novo AML treated with the "7 + 3" induction regimen. We analyzed RNA-sequencing profiles of whole bone marrow samples from 52 de novo AML patients who completed the "7 + 3" regimen and stratified patients into CR (n = 35) and non-CR (n = 17) groups. A systematic gene set analysis revealed significant associations between chemoresistance and mTOR (P < .001), myc (P < .001), mitochondrial oxidative phosphorylation (P < .001), and stemness (P = .002). These functions were independent with regard to gene contents and activity scores. An integration of these four functions showed a prediction of chemoresistance (area under the receiver operating characteristic curve = 0.815) superior to that of each function alone. Moreover, our proposed seven-gene scoring system significantly correlated with the four-function model (r = .97; P < .001) to predict chemoresistance to the "7 + 3" regimen. On multivariate analysis, a seven-gene score of ≥-0.027 (hazard ratio: 11.18; 95% confidence interval: 2.06-60.65; P = .005) was an independent risk factor for induction failure. Myc, OXPHOS, mTOR, and stemness were responsive for chemoresistance in AML. Treatments other than the "7 + 3" regimen need to be considered for de novo AML patients predicted to be refractory to the "7 + 3" regimen.

ACS Style

Yu-Chiao Chiu; Tzu‐Hung Hsiao; Jia‐Rong Tsai; Li‐Ju Wang; Tzu‐Chieh Ho; Shih‐Lan Hsu; Chieh‐Lin Jerry Teng. Integrating resistance functions to predict response to induction chemotherapy in de novo acute myeloid leukemia. European Journal of Haematology 2019, 103, 417 -425.

AMA Style

Yu-Chiao Chiu, Tzu‐Hung Hsiao, Jia‐Rong Tsai, Li‐Ju Wang, Tzu‐Chieh Ho, Shih‐Lan Hsu, Chieh‐Lin Jerry Teng. Integrating resistance functions to predict response to induction chemotherapy in de novo acute myeloid leukemia. European Journal of Haematology. 2019; 103 (4):417-425.

Chicago/Turabian Style

Yu-Chiao Chiu; Tzu‐Hung Hsiao; Jia‐Rong Tsai; Li‐Ju Wang; Tzu‐Chieh Ho; Shih‐Lan Hsu; Chieh‐Lin Jerry Teng. 2019. "Integrating resistance functions to predict response to induction chemotherapy in de novo acute myeloid leukemia." European Journal of Haematology 103, no. 4: 417-425.

Review
Published: 09 August 2019 in International Journal of Molecular Sciences
Reads 0
Downloads 0

Cyclin-dependent kinase 5 (CDK5) is a unique member of the cyclin-dependent kinase family. CDK5 is activated by binding with its regulatory proteins, mainly p35, and its activation is essential in the development of the central nervous system (CNS) and neurodegeneration. Recently, it has been reported that CDK5 plays important roles in regulating various biological and pathological processes, including cancer progression. Concerning prostate cancer, the androgen receptor (AR) is majorly involved in tumorigenesis, while CDK5 can phosphorylate AR and promotes the proliferation of prostate cancer cells. Clinical evidence has also shown that the level of CDK5 is associated with the progression of prostate cancer. Interestingly, inhibition of CDK5 prevents prostate cancer cell growth, while drug-triggered CDK5 hyperactivation leads to apoptosis. The blocking of CDK5 activity by its small interfering RNAs (siRNA) or Roscovitine, a pan-CDK inhibitor, reduces the cellular AR protein level and triggers the death of prostate cancer cells. Thus, CDK5 plays a crucial role in the growth of prostate cancer cells, and AR regulation is one of the important pathways. In this review paper, we summarize the significant studies on CDK5-mediated regulation of prostate cancer cells. We propose that the CDK5–p35 complex might be an outstanding candidate as a diagnostic marker and potential target for prostate cancer treatment in the near future.

ACS Style

Muhammet Oner; Eugene Lin; Mei-Chih Chen; Fu-Ning Hsu; G. M. Shazzad Hossain Prince; Kun-Yuan Chiu; Chieh-Lin Jerry Teng; Tsung-Ying Yang; Hsin-Yi Wang; Chia-Herng Yue; Ching-Han Yu; Chih-Ho Lai; Jer-Tsong Hsieh; Ho Lin. Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications. International Journal of Molecular Sciences 2019, 20, 3881 .

AMA Style

Muhammet Oner, Eugene Lin, Mei-Chih Chen, Fu-Ning Hsu, G. M. Shazzad Hossain Prince, Kun-Yuan Chiu, Chieh-Lin Jerry Teng, Tsung-Ying Yang, Hsin-Yi Wang, Chia-Herng Yue, Ching-Han Yu, Chih-Ho Lai, Jer-Tsong Hsieh, Ho Lin. Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications. International Journal of Molecular Sciences. 2019; 20 (16):3881.

Chicago/Turabian Style

Muhammet Oner; Eugene Lin; Mei-Chih Chen; Fu-Ning Hsu; G. M. Shazzad Hossain Prince; Kun-Yuan Chiu; Chieh-Lin Jerry Teng; Tsung-Ying Yang; Hsin-Yi Wang; Chia-Herng Yue; Ching-Han Yu; Chih-Ho Lai; Jer-Tsong Hsieh; Ho Lin. 2019. "Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications." International Journal of Molecular Sciences 20, no. 16: 3881.

Original report
Published: 20 April 2019 in Transplant Infectious Disease
Reads 0
Downloads 0

Owing to the shortage of hematopoietic stem cells from matched sibling donors (MSD) and matched unrelated donors (MUD), the number of patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation (allo-HSCT) has rapidly increased. Despite a comparable overall survival (OS) and leukemia-free survival using this approach, some evidence suggests that haploidentical allo-HSCT recipients have a higher incidence of cytomegalovirus (CMV) infection, though this has not been clearly established. This study retrospectively compared the cumulative incidence of CMV DNAemia, 2-year OS, and leukemia-free survival rates in acute leukemia patients with MSD (n = 41), MUD (n = 18), and haploidentical donor allografts (n = 21). The cumulative incidences of CMV DNAemia at day 180 in the MSD, MUD, and haploidentical groups were 39.0, 55.6, and 85.7%, respectively (P < 0.000). As less than 50% of patients in the MSD group were detected to have CMV DNAemia, the median time to CMV DNAemia detection in patients allografted with MSD could not be obtained. However, it was 42 and 29 days, respectively, for the MUD and haploidentical groups. Multivariate analysis revealed that haploidentical allo-HSCT (MSD vs. haploidentical: HR: 0.26; 95% CI: 0.09-0.78; P = 0.017) and age (HR: 1.03; 95% CI: 1.01-1.06; P = 0.011) increased CMV infection. Finally, MSD, MUD, and haploidentical allo-HSCT provided comparable 2-year OS rates (52.1%, 65.5%, and 65.6%; P = 0.425) and 2-year leukemia-free survival rates (67.1%, 68.3%, and 80.7%, P = 0.837). The CMV incidence was higher for haploidentical allo-HSCT than for MSD and MUD allo-HSCT; this could be explained by graft-versus-host disease prophylaxis by multiple immunosuppressants.

ACS Style

Cheng‐Hsien Lin; Yi‐Jiun Su; Chiann‐Yi Hsu; Po‐Nan Wang; Chieh‐Lin Jerry Teng. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia. Transplant Infectious Disease 2019, 21, e13096 .

AMA Style

Cheng‐Hsien Lin, Yi‐Jiun Su, Chiann‐Yi Hsu, Po‐Nan Wang, Chieh‐Lin Jerry Teng. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia. Transplant Infectious Disease. 2019; 21 (4):e13096.

Chicago/Turabian Style

Cheng‐Hsien Lin; Yi‐Jiun Su; Chiann‐Yi Hsu; Po‐Nan Wang; Chieh‐Lin Jerry Teng. 2019. "Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia." Transplant Infectious Disease 21, no. 4: e13096.

Journal article
Published: 28 March 2019 in Toxins
Reads 0
Downloads 0

Arecoline is the primary alkaloid in betel nuts, which are known as a risk factor for oral submucosal fibrosis and oral cancer. Lung cancer is a severe type of carcinoma with high cell motility that is difficult to treat. However, the detailed mechanisms of the correlation between Arecoline and lung cancer are not fully understood. Here, we investigated the effect of Arecoline on migration in lung cancer cell lines and its potential mechanism through the muscarinic acetylcholine receptor 3 (mAChR3)-triggered EGFR/Src/FAK pathway. Our results indicate that different concentrations of Arecoline treatment (10 µM, 20 µM, and 40 µM) significantly increased the cell migration ability in A549 and CL1-0 cells and promoted the formation of the filamentous actin (F-actin) cytoskeleton, which is a crucial element for cell migration. However, migration of H460, CL1-5, and H520 cell lines, which have a higher migration ability, was not affected by Arecoline treatment. The EGFR/c-Src/Fak pathway, which is responsible for cell migration, was activated by Arecoline treatment, and a decreased expression level of E-cadherin, which is an epithelial marker, was observed in Arecoline-treated cell lines. Blockade of the EGFR/c-Src/Fak pathway with the inhibitors of EGFR (Gefitinib) or c-Src (Dasatinib) significantly prevented Arecoline-promoted migration in A549 cells. Gefitinib or Dasatinib treatment significantly disrupted the Arecoline-induced localization of phospho-Y576-Fak during focal adhesion in A549 cells. Interestingly, Arecoline-promoted migration in A549 cells was blocked by a specific mAChR3 inhibitor (4-DAMP) or a neutralizing antibody of matrix metalloproteinase (MMP7 or Matrilysin). Taken together, our findings suggest that mAChR3 might play an essential role in Arecoline-promoted EGFR/c-Src/Fak activation and migration in an A549 lung cancer cell line.

ACS Style

Chih-Hsiang Chang; Mei-Chih Chen; Te-Huan Chiu; Yu-Hsuan Li; Wan-Chen Yu; Wan-Ling Liao; Muhammet Oner; Chang-Tze Ricky Yu; Chun-Chi Wu; Tsung-Ying Yang; Chieh-Lin Jerry Teng; Kun-Yuan Chiu; Kun-Chien Chen; Hsin-Yi Wang; Chia-Herng Yue; Chih-Ho Lai; Jer-Tsong Hsieh; Ho Lin. Arecoline Promotes Migration of A549 Lung Cancer Cells through Activating the EGFR/Src/FAK Pathway. Toxins 2019, 11, 185 .

AMA Style

Chih-Hsiang Chang, Mei-Chih Chen, Te-Huan Chiu, Yu-Hsuan Li, Wan-Chen Yu, Wan-Ling Liao, Muhammet Oner, Chang-Tze Ricky Yu, Chun-Chi Wu, Tsung-Ying Yang, Chieh-Lin Jerry Teng, Kun-Yuan Chiu, Kun-Chien Chen, Hsin-Yi Wang, Chia-Herng Yue, Chih-Ho Lai, Jer-Tsong Hsieh, Ho Lin. Arecoline Promotes Migration of A549 Lung Cancer Cells through Activating the EGFR/Src/FAK Pathway. Toxins. 2019; 11 (4):185.

Chicago/Turabian Style

Chih-Hsiang Chang; Mei-Chih Chen; Te-Huan Chiu; Yu-Hsuan Li; Wan-Chen Yu; Wan-Ling Liao; Muhammet Oner; Chang-Tze Ricky Yu; Chun-Chi Wu; Tsung-Ying Yang; Chieh-Lin Jerry Teng; Kun-Yuan Chiu; Kun-Chien Chen; Hsin-Yi Wang; Chia-Herng Yue; Chih-Ho Lai; Jer-Tsong Hsieh; Ho Lin. 2019. "Arecoline Promotes Migration of A549 Lung Cancer Cells through Activating the EGFR/Src/FAK Pathway." Toxins 11, no. 4: 185.

Comparative study
Published: 05 December 2017 in International Journal of Rheumatic Diseases
Reads 0
Downloads 0

Previous epidemiological studies have shown that autoimmune diseases increase the risk of lymphoma development. However, whether autoimmune diseases deteriorate the outcomes for lymphoma patients remains unclear. This study aimed to identify the clinical features of lymphoma patients with pre-existing autoimmune diseases. Whether pre-existing autoimmune diseases impacted progression-free survival (PFS) and overall survival (OS) in lymphoma patients was further investigated.We retrospectively reviewed medical records of 913 newly diagnosed lymphoma patients from January 2008 to November 2016. Thirty-four lymphoma patients with pre-existing autoimmune disorders were identified. Six of these 34 patients were lost to follow-up; their data was used to examine baseline clinical characteristics but not survival. Therefore, 28 lymphoma patients with autoimmune diseases were included in the autoimmune disease group for comparing the remission rate, PFS and OS to lymphoma patients without autoimmune diseases (control group; n = 56).Diffuse large B-cell lymphoma was the most common histological subtype (18/34; 52.94%). Complete remission rates in the autoimmune disease and control groups were 72.0% and 83.3%, respectively (P = 0.178). Patients with and without autoimmune diseases had similar PFS (45.4 ± 59.9 months vs. 51.5 ± 42.8 months; P = 0.398) and OS (46.4 ± 52.6 months vs. 50.1 ± 47.3 months; P = 0.352). By univariate analysis, pre-existing autoimmune diseases were not associated with inferior PFS (P = 0.326) or OS (P = 0.627).Lymphoma patients with and without autoimmune disorders had comparable outcomes. Autoimmune diseases are not an obstacle to lymphoma treatment.

ACS Style

Yu-Hsuan Shih; Youngsen Yang; Kuang-Hsi Chang; Yi-Hsing Chen; Chieh-Lin Jerry Teng. Clinical features and outcome of lymphoma patients with pre-existing autoimmune diseases. International Journal of Rheumatic Diseases 2017, 21, 93 -101.

AMA Style

Yu-Hsuan Shih, Youngsen Yang, Kuang-Hsi Chang, Yi-Hsing Chen, Chieh-Lin Jerry Teng. Clinical features and outcome of lymphoma patients with pre-existing autoimmune diseases. International Journal of Rheumatic Diseases. 2017; 21 (1):93-101.

Chicago/Turabian Style

Yu-Hsuan Shih; Youngsen Yang; Kuang-Hsi Chang; Yi-Hsing Chen; Chieh-Lin Jerry Teng. 2017. "Clinical features and outcome of lymphoma patients with pre-existing autoimmune diseases." International Journal of Rheumatic Diseases 21, no. 1: 93-101.

Journal article
Published: 09 August 2016 in Supportive Care in Cancer
Reads 0
Downloads 0

Understanding of pathogenesis and treatment for acute myeloid leukemia (AML) is growing. However, studies regarding the outcomes and late effects among AML survivors are relatively limited. This nationwide population-based study used medical records from the Taiwanese National Health Insurance Research Database. A total of 3356 AML patients diagnosed from 2000 to 2008 were analyzed. The physiological and psychological morbidities in AML survivors were compared to those identified from a normal population. This study also compared late effects among AML survivors treated by intensive chemotherapy alone and allogeneic hematopoietic stem cell transplantation (allo-HSCT). The incidence of AML in Taiwan has increased from 1.07 per 100,000 persons in 2000 to 2.17 per 100,000 persons in 2008 (p < 0.0001). With the median overall survival (OS) time of 0.98 years, 25.0 % of AML patients in this study cohort received best supportive care alone. Compared to the normal population, AML survivors had higher rates of hypertension (hazard ratio [HR] 1.69; 95 % confidence interval [CI] 1.18–2.42; p < 0.01), cardiovascular disease (HR 2.53; 95 % CI 1.39–4.61; p < 0.01), diabetes (HR 2.27; 95 % CI 1.48–3.48; p < 0.001), and psychological disorders (HR 1.45; 95 % CI 1.04–2.04; p < 0.05). Although patients undergoing allo-HSCT had a better OS than did patients treated with intensive chemotherapy alone (median not reached vs. 1.53 years; p < 0.0001), diabetes was found more often among allo-HSCT recipients than among patients receiving intensive chemotherapy only (HR 2.93; 95 % CI 1.21–7.08; p < 0.05). Regular physical and psychological surveillance of AML survivors is needed especially for those receiving allo-HSCT.

ACS Style

Kuang-Hsi Chang; Wen-Li Hwang; Chih-Hsin Muo; Chung Y. Hsu; Chieh-Lin Jerry Teng. Outcome and late effects among acute myeloid leukemia survivors: a nationwide population-based study. Supportive Care in Cancer 2016, 24, 4993 -5000.

AMA Style

Kuang-Hsi Chang, Wen-Li Hwang, Chih-Hsin Muo, Chung Y. Hsu, Chieh-Lin Jerry Teng. Outcome and late effects among acute myeloid leukemia survivors: a nationwide population-based study. Supportive Care in Cancer. 2016; 24 (12):4993-5000.

Chicago/Turabian Style

Kuang-Hsi Chang; Wen-Li Hwang; Chih-Hsin Muo; Chung Y. Hsu; Chieh-Lin Jerry Teng. 2016. "Outcome and late effects among acute myeloid leukemia survivors: a nationwide population-based study." Supportive Care in Cancer 24, no. 12: 4993-5000.

Journal article
Published: 23 May 2013 in Annals of Hematology
Reads 0
Downloads 0

Lymphoma-associated hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal disease. Differences between B cell and T cell lymphoma-associated HLH remain unclear, specifically clinical characteristics and survival. We retrospectively analyzed 30 lymphoma-associated HLH patients from July 2004 to October 2012. Patients were divided into B cell (n = 13) and T cell (n = 17) lymphoma groups. Patients’ age, performance status, presence of Epstein–Barr virus infection, international prognostic index, presence of disseminated intravascular coagulopathy, serum triglyceride, fibrinogen, and lactate dehydrogenase levels were not significantly different between B cell and T cell lymphoma groups. HLH was an indicator for treatment resistance in patients with B cell (p = 0.048), but not T cell (p = 0.217), lymphoma. Patients in the T cell lymphoma group, however, had higher serum ferritin levels than patients in the B cell lymphoma group (11,525.6 versus 3,790.6 ng/mL; p = 0.043). The median survival time for patients in the B cell and T cell lymphoma groups was 330 and 96 days, respectively. Although the difference was not statistically significant (p = 0.273), our results suggested a trend toward a better overall survival time in patients with B cell lymphoma. This survival advantage could be at least partially due to use of rituximab (p = 0.045) for the treatment of patients with B cell lymphoma. Our results also suggested that allogeneic hematopoietic stem cell transplantation could possibly provide survival benefits to T cell lymphoma-associated HLH by graft-versus-lymphoma effect.

ACS Style

Jui-Ting Yu; Chen-Yu Wang; Youngsen Yang; Ren-Ching Wang; Kuang-Hsi Chang; Wen-Li Hwang; Chieh-Lin Jerry Teng. Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Annals of Hematology 2013, 92, 1529 -1536.

AMA Style

Jui-Ting Yu, Chen-Yu Wang, Youngsen Yang, Ren-Ching Wang, Kuang-Hsi Chang, Wen-Li Hwang, Chieh-Lin Jerry Teng. Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Annals of Hematology. 2013; 92 (11):1529-1536.

Chicago/Turabian Style

Jui-Ting Yu; Chen-Yu Wang; Youngsen Yang; Ren-Ching Wang; Kuang-Hsi Chang; Wen-Li Hwang; Chieh-Lin Jerry Teng. 2013. "Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution." Annals of Hematology 92, no. 11: 1529-1536.

Journal article
Published: 01 January 2013 in World Journal of Surgical Oncology
Reads 0
Downloads 0

Malignancy-associated spinal cord compression is generally treated by surgical decompression, radiotherapy or a combination of both. Since diffuse large B-cell lymphoma (DLBCL) is highly sensitive to both chemotherapy and radiotherapy, the role of surgical decompression in the treatment of DLBCL-associated spinal cord compression remains unclear. We therefore conducted a retrospective review to investigate the impact of surgical decompression on recovery from neurological deficit caused by DLBCL-associated spinal cord compression and patients’ overall survival. Between March 2001 and September 2011, 497 newly diagnosed DLBCL patients were reviewed, and 11 cases had DLBCL-associated spinal cord compression. Six cases were treated surgically and five cases nonsurgically. The rates of complete recovery from neurological deficit were 100% (6/6) and 20% (1/5) for patients in the surgical and nonsurgical groups, respectively (P = 0.015), while the median survival for patients in the surgical and nonsurgical groups was 48.6 months and 17.8 months, respectively (P = 0.177). We conclude that surgical decompression can improve recovery from neurological deficit in patients with DLBCL-associated spinal cord compression, possibly providing these patients a survival benefit.

ACS Style

Ching-Ming Chang; Hung-Chieh Chen; Youngsen Yang; Ren-Ching Wang; Wen-Li Hwang; Chieh-Lin Jerry Teng. Surgical decompression improves recovery from neurological deficit and may provide a survival benefit in patients with diffuse large B-cell lymphoma-associated spinal cord compression: a case-series study. World Journal of Surgical Oncology 2013, 11, 90 -90.

AMA Style

Ching-Ming Chang, Hung-Chieh Chen, Youngsen Yang, Ren-Ching Wang, Wen-Li Hwang, Chieh-Lin Jerry Teng. Surgical decompression improves recovery from neurological deficit and may provide a survival benefit in patients with diffuse large B-cell lymphoma-associated spinal cord compression: a case-series study. World Journal of Surgical Oncology. 2013; 11 (1):90-90.

Chicago/Turabian Style

Ching-Ming Chang; Hung-Chieh Chen; Youngsen Yang; Ren-Ching Wang; Wen-Li Hwang; Chieh-Lin Jerry Teng. 2013. "Surgical decompression improves recovery from neurological deficit and may provide a survival benefit in patients with diffuse large B-cell lymphoma-associated spinal cord compression: a case-series study." World Journal of Surgical Oncology 11, no. 1: 90-90.

Journal article
Published: 05 November 2012 in Function of a membrane-embedded domain evolutionarily multiplied in the GPI lipid anchor pathway proteins PIG-B, PIG-M, PIG-U, PIG-W, PIG-V, and PIG-Z
Reads 0
Downloads 0

FBXW7, a component of E3 ubiquitin ligase, plays an important role in mitotic checkpoint, but its role remains unclear. Aurora B is a mitotic checkpoint kinase that plays a pivotal role in mitosis by ensuring correct chromosome segregation and normal progression through mitosis. Whether Aurora B and FBXW7 are coordinately regulated during mitosis is not known. Here, we show that FBXW7 is a negative regulator for Aurora B. Ectopic expression of FBXW7 can suppress the expression of Aurora B. Accordingly, FBXW7 deficiency leads to Aurora B elevation. Mechanistic studies show that all FBXW7 isoforms are negative regulators of Aurora B expression through ubiquitination-mediated protein degradation. Aurora B interacts with R465 and R505 residues of WD 40 domain of FBXW7. Significantly, inverse correlation between FBXW7 and Aurora B elevation is translated into the deregulation of mitosis. FBWX7 expression mitigates Aurora B-mediated cell growth and mitotic deregulation. In addition, FBXW7 reduces the percentage of multinucleated cells caused by Aurora B overexpression. These data suggest that FBXW7 is an important negative regulator of Aurora B, and that the loss or mutation of FBXW7 as seen in many types of cancer could lead to an abnormal elevation of Aurora B and result in deregulated mitosis, which accelerates cancer cell growth.

ACS Style

Chieh-Lin Teng; Yun-Chi Hsieh; Liem Phan; Jihyun Shin; Chris Gully; Guermarie Velazquez-Torres; Stephen Skerl; Sai-Ching J. Yeung; Shih-Lan Hsu; Mong-Hong Lee. FBXW7 is involved in Aurora B degradation. Function of a membrane-embedded domain evolutionarily multiplied in the GPI lipid anchor pathway proteins PIG-B, PIG-M, PIG-U, PIG-W, PIG-V, and PIG-Z 2012, 11, 4059 -4068.

AMA Style

Chieh-Lin Teng, Yun-Chi Hsieh, Liem Phan, Jihyun Shin, Chris Gully, Guermarie Velazquez-Torres, Stephen Skerl, Sai-Ching J. Yeung, Shih-Lan Hsu, Mong-Hong Lee. FBXW7 is involved in Aurora B degradation. Function of a membrane-embedded domain evolutionarily multiplied in the GPI lipid anchor pathway proteins PIG-B, PIG-M, PIG-U, PIG-W, PIG-V, and PIG-Z. 2012; 11 (21):4059-4068.

Chicago/Turabian Style

Chieh-Lin Teng; Yun-Chi Hsieh; Liem Phan; Jihyun Shin; Chris Gully; Guermarie Velazquez-Torres; Stephen Skerl; Sai-Ching J. Yeung; Shih-Lan Hsu; Mong-Hong Lee. 2012. "FBXW7 is involved in Aurora B degradation." Function of a membrane-embedded domain evolutionarily multiplied in the GPI lipid anchor pathway proteins PIG-B, PIG-M, PIG-U, PIG-W, PIG-V, and PIG-Z 11, no. 21: 4059-4068.

Case reports
Published: 16 July 2012 in World Journal of Surgical Oncology
Reads 0
Downloads 0

Primary splenic diffuse large B-cell lymphoma (DLBCL) is a rare clinical condition, which is generally treated by six to eight cycles of chemotherapy involving a combination of rituximab and the cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP) regimen. However, the treatment for chemorefractory primary splenic DLBCL remains controversial. Therapeutic splenic irradiation (SI) might be a reasonable and possibly the only treatment option with curative intention for patients with chemorefractory primary splenic DLBCL. However, the efficacy and safety of therapeutic SI are unclear. Herein, we present the case of a primary splenic DLBCL patient who was refractory to multiple chemotherapy regimens but achieved complete remission after administration of therapeutic SI. However, his condition was complicated with severe gastric variceal bleeding due to splenic venous thrombosis, which was successfully treated via splenectomy and short gastric vein ligation. On the basis of our findings, we concluded that the splenic venous thrombosis-induced gastric variceal bleeding was a rare but life-threatening adverse effect of the therapeutic SI administered for primary splenic DLBCL. Surgical intervention involving splenectomy and short gastric vein ligation is mandatory and should be performed as soon as possible for such patients.

ACS Style

Ying-Chu Lin; Hung-Chieh Chen; Shao-Bing Cheng; Wen-Li Hwang; Ren-Ching Wang; Chieh-Lin Jerry Teng. Splenic irradiation-induced gastric variceal bleeding in a primary splenic diffuse large B-cell lymphoma patient: a rare complication successfully treated by splenectomy with short gastric vein ligation. World Journal of Surgical Oncology 2012, 10, 150 -150.

AMA Style

Ying-Chu Lin, Hung-Chieh Chen, Shao-Bing Cheng, Wen-Li Hwang, Ren-Ching Wang, Chieh-Lin Jerry Teng. Splenic irradiation-induced gastric variceal bleeding in a primary splenic diffuse large B-cell lymphoma patient: a rare complication successfully treated by splenectomy with short gastric vein ligation. World Journal of Surgical Oncology. 2012; 10 (1):150-150.

Chicago/Turabian Style

Ying-Chu Lin; Hung-Chieh Chen; Shao-Bing Cheng; Wen-Li Hwang; Ren-Ching Wang; Chieh-Lin Jerry Teng. 2012. "Splenic irradiation-induced gastric variceal bleeding in a primary splenic diffuse large B-cell lymphoma patient: a rare complication successfully treated by splenectomy with short gastric vein ligation." World Journal of Surgical Oncology 10, no. 1: 150-150.

Journal article
Published: 01 January 2012 in World Journal of Surgical Oncology
Reads 0
Downloads 0

Orthotopic liver transplantation (OLT) is one of the most effective treatments for patients with hepatocellular carcinoma (HCC) within the Milan criteria. However, for patients beyond these criteria, the recurrence rate is higher and the prognosis is worse. Sorafenib is the only drug showing survival benefits in advanced HCC patients; however, its role in patients beyond the Milan criteria after OLT remains unclear and requires further investigation. As a case-control study, we retrospectively analyzed 17 Chinese patients beyond Milan criteria undergoing OLT for HCC. These patients were stratified into adjuvant (n = 5), palliative (n = 6), and control groups (n = 6). Nine of 11 patients who received sorafenib after OLT needed dose reduction due to more than grade 2 side effects. The disease-free survival rates for patients with or without adjuvant sorafenib were 100% versus 37.5% (p = 0.034) at 6 months, 66.7% versus 9.4% (p = 0.026) at 12 months, and 66.7% versus 0.0% (p = 0.011) at 18 months, respectively. The overall survival rates for patients in palliative and control groups were 66.7% versus 40.0% (p = 0.248) at 6 months, 66.7% versus 40.0% (p = 0.248) at 12 months, and 50.0% versus 20.0% (p = 0.17) at 18 months, respectively. Patients in the adjuvant group had better overall survival rates than those in the palliative and control groups (p = 0.031) at 24-month follow-up. Adjuvant sorafenib could possibly extend both disease-free and overall survival for HCC patients beyond Milan criteria after OLT.

ACS Style

Chieh-Lin Teng; Wen-Li Hwang; Yi-Ju Chen; Kuang-Hsi Chang; Shao-Bin Cheng. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study. World Journal of Surgical Oncology 2012, 10, 41 -41.

AMA Style

Chieh-Lin Teng, Wen-Li Hwang, Yi-Ju Chen, Kuang-Hsi Chang, Shao-Bin Cheng. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study. World Journal of Surgical Oncology. 2012; 10 (1):41-41.

Chicago/Turabian Style

Chieh-Lin Teng; Wen-Li Hwang; Yi-Ju Chen; Kuang-Hsi Chang; Shao-Bin Cheng. 2012. "Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study." World Journal of Surgical Oncology 10, no. 1: 41-41.

Journal article
Published: 18 September 2010 in Annals of Hematology
Reads 0
Downloads 0

Dear Editor, Reversible posterior leukoencephalopathy (RPLS) is an uncommon disease characterized by white matter angioedema over occipital lobes [1]. Possible etiologies of RPLS are cytotoxic agents [2], connective tissue disorders [3], and even rituximab, an anti-CD20 monoclonal antibody [4, 5]. Here we report a case of refractory immune thrombocytopenic purpura (ITP) with presentations of convulsions and conscious disturbance indicating RPLS. Weekly rituximab induced complete recovery from thrombocytopenia. Complete resolution of brain lesions confirmed diagnosis of RPLS. A 35-year-old woman, without any other systemic diseases, presented with gum bleeding without fever for 5 days. Except for having severe thrombocytopenia (platelet: 2 × 109/L, normal: 140 × 109 to 400 × 109/L), her initial hemogram was normal. Antinuclear antibody was weakly positive (1:80). She had normal renal and thyroid function. Megakaryocyte hyperplasia was the only positive finding in bone marrow examination.

ACS Style

Ching-Yeh Lin; Hung-Chieh Chen; Wen-Lee Hwang; Chieh-Lin Teng. Immune thrombocytopenic pupura-induced reversible posterior leukoencephalopathy successfully treated by rituximab. Annals of Hematology 2010, 90, 731 -732.

AMA Style

Ching-Yeh Lin, Hung-Chieh Chen, Wen-Lee Hwang, Chieh-Lin Teng. Immune thrombocytopenic pupura-induced reversible posterior leukoencephalopathy successfully treated by rituximab. Annals of Hematology. 2010; 90 (6):731-732.

Chicago/Turabian Style

Ching-Yeh Lin; Hung-Chieh Chen; Wen-Lee Hwang; Chieh-Lin Teng. 2010. "Immune thrombocytopenic pupura-induced reversible posterior leukoencephalopathy successfully treated by rituximab." Annals of Hematology 90, no. 6: 731-732.

Journal article
Published: 15 December 2009 in Annals of Hematology
Reads 0
Downloads 0

Dear Editor, We report a patient of monoclonal gammopathy of undetermined significance (MGUS) with manifestation of pyoderma gangrenosum refractory to steroids and chemotherapy. Both the M-protein and pyoderma gangrenosum disappeared after autologous peripheral blood stem cell transplantation (PBSCT). A 33-year-old man suffered from rapidly enlarging pustular papules and plagues that ulcerated the necrotic base over his left leg 5 years ago (Fig. 1a). His serum immunoelectrophoresis revealed IgA-λ monoclonal gammopathy (IgA 782 mg/dL, normal 70–400 mg/dL; κ/λ 1.17, normal 1.35–2.69). Bone marrow examination disclosed slight plasmacytosis, which was less than 10% of all the nucleated cells (Fig. 1b). Without anemia (hemoglobin, 12.7 mg/dl; normal, 12–14 mg/dl), thrombocytopenia (platelet count, 426 × 109/l; normal, 150–430 × 109/l), osteolytic lesions, and impaired renal function, he was diagnosed as MGUS, IgA-λ, complicated with pyoderma gangrenosum. Fig. 1a–c Pyoderma gangrenosum. Large

ACS Style

Ching-Ming Chang; Wen-Lee Hwang; Zu-Yi Hsieh; Ren-Ching Wang; Chieh-Lin Teng. Monoclonal gammopathy of undetermined significance related pyoderma gangrenosum successfully treated with autologous peripheral blood stem cell transplantation. Annals of Hematology 2009, 89, 823 -824.

AMA Style

Ching-Ming Chang, Wen-Lee Hwang, Zu-Yi Hsieh, Ren-Ching Wang, Chieh-Lin Teng. Monoclonal gammopathy of undetermined significance related pyoderma gangrenosum successfully treated with autologous peripheral blood stem cell transplantation. Annals of Hematology. 2009; 89 (8):823-824.

Chicago/Turabian Style

Ching-Ming Chang; Wen-Lee Hwang; Zu-Yi Hsieh; Ren-Ching Wang; Chieh-Lin Teng. 2009. "Monoclonal gammopathy of undetermined significance related pyoderma gangrenosum successfully treated with autologous peripheral blood stem cell transplantation." Annals of Hematology 89, no. 8: 823-824.